A Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV Infection
This study allows patients who need a new anti-HIV treatment to take tenofovir disoproxil fumarate (tenofovir DF), an experimental drug. This study also looks at any side effects the drug causes.
|Study Design:||Primary Purpose: Treatment|
|Official Title:||An Open-Label, Multicenter, Compassionate Access Study of the Safety of Tenofovir Disoproxil Fumarate Administered in Combination With Other Antiretroviral Agents for the Treatment of HIV-1 Infected Patients|
|Study Start Date:||December 1999|
HIV-1-infected patients who are currently receiving stable antiretroviral therapy add tenofovir DF to their regimen. Study participation lasts for approximately 48 weeks. Interested patients should contact their physicians.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002453
|United States, California|
|Tenofovir Coordinating Center|
|Foster City, California, United States, 94404|